Movement Disorders and Mortality in Severely Mentally Ill Patients: The Curacao Extrapyramidal Syndromes Study XIV.
Tardive dyskinesia
akathisia
life expectancy
parkinsonism
schizophrenia
survival
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
21 06 2022
21 06 2022
Historique:
pubmed:
30
4
2022
medline:
24
6
2022
entrez:
29
4
2022
Statut:
ppublish
Résumé
There is a substantial gap in life expectancy between patients with severe mental illness (SMI) and the general population and it is important to understand which factors contribute to this difference. Research suggests an association between tardive dyskinesia (TD) and mortality; however, results are inconclusive. In addition, studies investigating associations between parkinsonism or akathisia and mortality are rare. We hypothesized that TD would be a risk factor for mortality in patients with SMI. We studied a cohort of 157 patients diagnosed predominantly with schizophrenia on the former Netherlands Antilles. TD, parkinsonism, and akathisia were assessed with rating scales on eight occasions over a period of 18 years. Twenty-four years after baseline, survival status and if applicable date of death were determined. Associations between movement disorders and survival were analyzed using Cox regression. Sex, age, antipsychotics, antidepressants and benzodiazepines at each measurement occasion were tested as covariates. Parkinsonism was a significant risk factor with an HR of 1.02 per point on the motor subscale of the Unified Parkinson's Disease Rating Scale (range 0-56). TD and akathisia were not significantly associated with mortality. Parkinsonism may be an important risk factor for mortality in SMI patients. This finding calls for more follow-up and intervention studies to confirm this finding and to explore whether treatment or prevention of parkinsonism can reduce excess mortality.
Sections du résumé
BACKGROUND AND HYPOTHESIS
There is a substantial gap in life expectancy between patients with severe mental illness (SMI) and the general population and it is important to understand which factors contribute to this difference. Research suggests an association between tardive dyskinesia (TD) and mortality; however, results are inconclusive. In addition, studies investigating associations between parkinsonism or akathisia and mortality are rare. We hypothesized that TD would be a risk factor for mortality in patients with SMI.
STUDY DESIGN
We studied a cohort of 157 patients diagnosed predominantly with schizophrenia on the former Netherlands Antilles. TD, parkinsonism, and akathisia were assessed with rating scales on eight occasions over a period of 18 years. Twenty-four years after baseline, survival status and if applicable date of death were determined. Associations between movement disorders and survival were analyzed using Cox regression. Sex, age, antipsychotics, antidepressants and benzodiazepines at each measurement occasion were tested as covariates.
STUDY RESULTS
Parkinsonism was a significant risk factor with an HR of 1.02 per point on the motor subscale of the Unified Parkinson's Disease Rating Scale (range 0-56). TD and akathisia were not significantly associated with mortality.
CONCLUSIONS
Parkinsonism may be an important risk factor for mortality in SMI patients. This finding calls for more follow-up and intervention studies to confirm this finding and to explore whether treatment or prevention of parkinsonism can reduce excess mortality.
Identifiants
pubmed: 35486807
pii: 6576125
doi: 10.1093/schbul/sbac037
pmc: PMC9212096
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
766-773Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Arch Gen Psychiatry. 2007 Oct;64(10):1123-31
pubmed: 17909124
World Psychiatry. 2020 Feb;19(1):61-68
pubmed: 31922669
Eur Arch Psychiatry Clin Neurosci. 2014 Feb;264(1):3-28
pubmed: 23942824
Keio J Med. 1989 Mar;38(1):70-2
pubmed: 2716220
Am J Psychiatry. 1984 Aug;141(8):1018-9
pubmed: 6465365
Front Psychol. 2021 Aug 06;12:708361
pubmed: 34421759
J Clin Psychopharmacol. 2000 Apr;20(2):188-94
pubmed: 10770457
Schizophr Res. 2011 Sep;131(1-3):101-4
pubmed: 21741216
Lancet. 2009 Aug 22;374(9690):620-7
pubmed: 19595447
Am J Psychiatry. 2016 Jun 1;173(6):600-6
pubmed: 26651392
Am J Psychiatry. 1979 Sep;136(9):1228
pubmed: 474829
Schizophr Res. 1996 May;19(2-3):195-203
pubmed: 8789918
Biol Psychiatry. 1990 Sep 15;28(6):502-8
pubmed: 1977478
Schizophr Res. 2008 Jan;98(1-3):79-83
pubmed: 17936588
World Psychiatry. 2011 Feb;10(1):52-77
pubmed: 21379357
JAMA Psychiatry. 2013 Sep;70(9):931-9
pubmed: 23863861
Curr Drug Abuse Rev. 2012 Sep;5(3):243-53
pubmed: 23030352
Int J Bipolar Disord. 2019 Mar 1;7(1):6
pubmed: 30820700
Acta Psychiatr Scand. 1987 Jan;75(1):74-7
pubmed: 2883815
Am J Psychiatry. 1978 Mar;135(3):371-2
pubmed: 626235
J Clin Psychopharmacol. 1998 Apr;18(2 Suppl 1):2S-4S
pubmed: 9555609
Ann Gen Psychiatry. 2017 Feb 15;16:12
pubmed: 28289436
Br J Psychiatry. 1986 Mar;148:310-6
pubmed: 3719224
Schizophr Res. 1997 Aug 29;26(2-3):235-42
pubmed: 9323356
Schizophr Bull. 2016 Nov;42(6):1486-1495
pubmed: 26994395
PLoS One. 2011;6(10):e25588
pubmed: 22022416
J Clin Psychiatry. 2006 Dec;67(12):1920-7
pubmed: 17194270
Br J Psychiatry. 2009 Apr;194(4):360-4
pubmed: 19336789
Psychol Med. 2017 Oct;47(13):2217-2228
pubmed: 28397632
J Clin Psychopharmacol. 2009 Feb;29(1):5-8
pubmed: 19142099
Br J Psychiatry. 1989 May;154:672-6
pubmed: 2574607
BMC Psychiatry. 2010 Sep 30;10:77
pubmed: 20920287
Eur Arch Psychiatry Clin Neurosci. 2015 Mar;265(2):147-54
pubmed: 24925606
Dysphagia. 2017 Aug;32(4):467-471
pubmed: 28447217
Arch Gen Psychiatry. 1982 Apr;39(4):486-7
pubmed: 6121550
J Nerv Ment Dis. 1985 Jun;173(6):353-7
pubmed: 3998720
Mov Disord. 1994 Jan;9(1):76-83
pubmed: 8139608
Schizophr Res. 2008 Mar;100(1-3):97-107
pubmed: 18055180
J Geriatr Psychiatry Neurol. 2018 Jan;31(1):19-26
pubmed: 29191070
Schizophr Bull. 2021 Jul 8;47(4):906-914
pubmed: 33764476
Neurology. 2010 Oct 5;75(14):1270-6
pubmed: 20921512
Compr Psychiatry. 2007 Sep-Oct;48(5):436-40
pubmed: 17707251
Eur Neuropsychopharmacol. 2008 Feb;18(2):152-5
pubmed: 17822885
BMC Psychiatry. 2014 Sep 12;14:261
pubmed: 25227899
Am J Psychiatry. 2013 Mar;170(3):324-33
pubmed: 23318474
Pharmacopsychiatry. 2009 Mar;42(2):57-60
pubmed: 19308879
Schizophr Bull. 2014 Sep;40(5):1164-73
pubmed: 24072809
Schizophr Bull. 2015 May;41(3):656-63
pubmed: 25422511